Use the Back button in your browser to see the other results of your search or to select another record.

Detailed Search Results

Tolerance and physiologic effects of nocturnal mask pressure support versus proportional assist ventilation in chronic ventilatory failure
Winck JC, Vitacca M, Morais A, Barbano L, Porta R, Teixeira-Pinto A, Ambrosino N
Chest 2004 Aug;126(2):382-388
clinical trial
5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed*

STUDY OBJECTIVES: To compare the tolerance and physiologic effects of a 5-night treatment with either nasal proportional assist ventilation (PAV) or pressure support ventilation (PSV) in patients with chronic ventilatory failure. DESIGN: Cross-over, randomized, controlled study. SETTING: Rehabilitation units of pneumology department. PATIENTS OR PARTICIPANTS: Four patients with COPD and 10 patients with restrictive thoracic diseases with chronic hypercapnia (median baseline PacO2 55.1 mmHg) were studied. INTERVENTIONS: In a cross-over study, nasal PAV and PSV set at the patient's comfort were randomly applied during 5 consecutive nights (with a 2-night washout period). MEASUREMENTS AND RESULTS: Continuous nocturnal pulse oximetric saturation (SpO2) and arterial blood gas results at wake-up were evaluated at baseline during spontaneous breathing and on the fifth day of ventilatory support. Dyspnea, sleep quality, adaptation, and comfort at inspiration and expiration by visual analog scale (VAS) were evaluated every day as well as a side effects score. On the fifth day, there were no significant differences in daytime PacO2 (median PAV 53.3 mmHg; median PSV, 50.2; p = 0.168). Mean nocturnal SpO2 improved significantly with both PAV and PSV without any significant differences between modes (baseline median 92%; PAV median 94.5%; PSV median 95%). The percentage of the study night spent < 90% SpO2 (T90) was slightly but significantly higher with PAV than with PSV (median PAV T90 4%; median PSV T90, 2%; p = 0.049). The VAS symptom score was similar at day 5 between modes; however, nasal and oral dryness were lower (p = 0.05) and alarm noise was higher (p = 0.037) with PAV. CONCLUSIONS: After 5 days of treatment, both modes had similar tolerance, and were equally effective in reducing daytime hypercapnia and improving nocturnal saturation and symptoms. However, PAV induced less nasal and oral dryness but was associated with higher alarm noise.

Full text (sometimes free) may be available at these link(s):      help